Galderma said Chapman, previously vice president of strategic access for Galderma’s prescription business unit, will manage Galderma’s portfolio of prescription products, including the full line of products that treat acne, psoriasis, eczema and rosacea.
He also will oversee Galderma CareConnect, a patient savings card program that offers patients discounts on the company’s dermatology prescription medications.
The U.S. medical solutions business of Nestlé Skin Health, Galderma has an extensive portfolio of prescription, consumer, and aesthetic and corrective treatments for patients, consumers and health care professionals, including flagship brands Epiduo Forte Gel, Soolantra Cream, Oracea Capsules, Cetaphil and the Restylane family of dermal fillers.
“Galderma has a rich portfolio of prescription products that truly change peoples’ lives,” Chapman stated. “I’m proud to be a part of the innovation that we deliver to both health care professionals and patients. And I look forward to leading the prescription business unit in continued advancements in skin health, especially for people suffering from skin diseases such as acne and rosacea.”
Chapman joined Galderma in 2015. As vice president of strategic access, he was responsible for commercial payer account management and contracting, trade account management and branded consumer rebate programs. During his tenure, he developed and launched the Galderma CareConnect program, which has grown to more than 40,000 pharmacies and served more than 500,000 patients. The program just reached a milestone with its 1 millionth prescription, according to Galderma.
“Chris joined Galderma with more than 25 years of pharmaceutical experience and has successfully leveraged his intimate knowledge of the pharmaceutical industry, specializing in payer and contracting, to modernize our prescription business in the face of price and access demands,” commented Miles Harrison, oresident and general manager of Galderma North America. “He is a proven business leader and the right person to lead the prescription business unit into the future.”